{
    "clinical_study": {
        "@rank": "116102", 
        "arm_group": {
            "arm_group_label": "Subject Treatment with IGF-Methotrexate", 
            "arm_group_type": "Experimental", 
            "description": "IGF-Methotrexate (iv infusion) at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle. Up to 7 dose levels will be tested, starting with 0.05 \u00b5equivalents per kg and up to 2.5 \u00b5equivalents per kg."
        }, 
        "brief_summary": {
            "textblock": "This phase I dose escalation study will evaluate IGF-Methotrexate conjugate (765IGF-MTX) in\n      patients with advanced, previously treated tumors.  765IGF-MTX is administered as an IV\n      infusion over 1 hour on days 1, 8 and 15 of a 28 day cycle.  Treatment continues until\n      disease progression, unacceptable toxicity, or patient refusal. Assessment of response will\n      be confirmed with imaging studies performed at the end of cycle 2, and every 2 weeks after."
        }, 
        "brief_title": "Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "Brain Cancer", 
            "Gastrointestinal Cancers", 
            "Genitourinary Cancers", 
            "Gynecologic Cancers", 
            "Head and Neck Cancers", 
            "Melanoma", 
            "Thoracic Cancers"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Brain Neoplasms", 
                "Breast Neoplasms", 
                "Head and Neck Neoplasms", 
                "Melanoma", 
                "Thoracic Neoplasms", 
                "Gastrointestinal Neoplasms", 
                "Urogenital Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Diagnosis of advanced malignancy, refractory to or intolerant to standard therapy and\n             is no longer likely to respond to such therapy.\n\n          2. Tumor must express IGF-1R, defined as 10% or higher of cells expressing IGF-1R by\n             IHC. Paraffin-embedded tissue sections will be stained with antibodies against IGFR-1\n             according to the manufacturer's recommended protocols. IHC staining will be performed\n             at the Pathology Department of the University of Illinois Cancer Center.\n\n          3. Measurable or evaluable disease per RECIST 1.1 criteria (appendix II).\n\n          4. Age \u2265 18 years.\n\n          5. ECOG performance status of 0, 1 or 2 (appendix IV).\n\n          6. Prior systemic chemotherapy, immunotherapy, or biological therapy, radiation therapy\n             and/or surgery are allowed; however prior use of methotrexate is not allowed.\n\n             Time since prior therapy and the first dose of study drug:\n\n               -  At least 2 weeks since prior radiation, non cytotoxic small molecule drugs\n                  (e.g., tyrosine kinase inhibitors such as erlotinib and hormonal agents such as\n                  letrozole), prior major surgery (surgery (defined as a surgery involving a risk\n                  to the life of the patient; specifically: an operation upon an organ within the\n                  cranium, chest, abdomen, or pelvic cavity), prior systemic FDA approved therapy\n\n               -  At least 3 weeks since prior antineoplastic therapy\n\n               -  At least 4 weeks since exposure to monoclonal antibodies (chimeric or fully\n                  human)\n\n               -  At least 6 weeks since prior nitrosureas or mitomycin-C\n\n          7. Patient must have recovered from the acute toxic effects (\u2264 grade 1 CTCAE v4) of\n             previous anti-cancer treatment prior to study enrollment; the only exception is that\n             grade 2 neuropathy is permitted\n\n          8. Adequate organ function within 14 days of study registration defined as:\n\n             Absolute neutrophil count (ANC) > 1.5 X 109/L Hemoglobin1 > 9 g/dL Platelets1 > 100 X\n             109/L Total bilirubin < 1.5 x ULN Alkaline Phosphatase, AST and ALT < 3 X ULN (< 5 x\n             ULN is acceptable if liver has tumor involvement) Serum Creatinine       \u2264 1.5 x ULN\n             Creatinine Clearance > 60 ml/min Note: Patient may not have had a transfusion within\n             7 days of blood draw.\n\n          9. Negative urine or serum pregnancy test in females.  Male and female patients with\n             reproductive potential must use an approved contraceptive method if appropriate (for\n             example, abstinence, oral contraceptives, implantable hormonal contraceptives, or\n             double barrier methods) during and for 3 months after the last dose of 765IGF-MTX.\n\n         10. Voluntary written informed consent before performance of any study-related procedure\n             not part of normal medical care, with the understanding that consent may be withdrawn\n             by the patient at any time without prejudice to future medical care.\n\n        Exclusion Criteria:\n\n          1. Untreated or symptomatic CNS metastases.\n\n          2. Radiation therapy to more than 25% of the bone marrow. Whole pelvic radiation is\n             considered to be over 25%.\n\n          3. \u2265 Grade 3 peripheral neuropathy within 14 days before enrollment.\n\n          4. Systemic infection requiring IV antibiotic therapy within 7 days preceding the first\n             dose of study drug, or other severe infection.\n\n          5. Myocardial infarction within 6 months prior to enrollment or has New York Heart\n             Association (NYHA - appendix IV) Class III or IV heart failure, uncontrolled angina,\n             severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of\n             acute ischemia or active conduction system abnormalities. Prior to study entry, any\n             ECG abnormality at Screening has to be documented by the investigator as not\n             medically relevant.\n\n          6. Pregnant or breastfeeding - methotrexate is Pregnancy Category X - has been reported\n             to cause fetal death and/or congenital abnormalities. Confirmation that the subject\n             is not pregnant must be established by a negative serum Beta-human chorionic\n             gonadotropin (Beta-hCG) pregnancy test result obtained during screening.  Pregnancy\n             testing is not required for post-menopausal or surgically sterilized women.\n\n          7. Uncontrolled diabetes mellitus defined as a Hemoglobin A1C\u2265 7% in patients with a\n             prior history of diabetes, 28 days prior to study enrollment.\n\n          8. Serious concomitant systemic disorders (e.g., active infection, uncontrolled\n             diabetes) or psychiatric disorders that, in the opinion of the investigator, would\n             compromise the safety of the patient or compromise the patient's ability to complete\n             the study.\n\n          9. Other severe acute or chronic medical or psychiatric conditions, or laboratory\n             abnormality that may increase the risk associated with study participation or\n             investigational product administration or may interfere with the interpretation of\n             study results and, in the judgment of the investigator, would make the patient\n             inappropriate for enrollment in this study.\n\n         10. Recent (within 6 months) arterial thromboembolic events, including transient ischemic\n             attack (TIA), cerebrovascular accident (CVA), unstable angina, or myocardial\n             infarction (MI).\n\n         11. History of abdominal fistula, gastrointestinal perforation, or intra abdominal\n             abscess within 28 days prior to beginning study treatment.\n\n         12. Abnormalities on 12-lead electrocardiogram (ECG) considered by the investigator to be\n             clinical significant or baseline prolongation of the rate-corrected QT interval\n             (e.g., repeated demonstration greater than 2 occasions of QTc interval > 450\n             milliseconds).\n\n         13. History of cerebrovascular accident, pulmonary embolism or untreated deep venous\n             thrombosis (DVT) within the past 6 months. Note: Subjects with recent DVT who have\n             been treated with therapeutic anticoagulants for at least 6 weeks are eligible.\n\n         14. Presence of any non-healing wound, fracture, or ulcer within 28 days prior to the\n             first dose of study drug.\n\n         15. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs\n             chemically related to IGF or methotrexate."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02045368", 
            "org_study_id": "2013-0655"
        }, 
        "intervention": {
            "arm_group_label": "Subject Treatment with IGF-Methotrexate", 
            "description": "765IGF-MTX (iv infusion) at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle.", 
            "intervention_name": "IGF-Methotrexate", 
            "intervention_type": "Drug", 
            "other_name": "765IGF-MTX"
        }, 
        "intervention_browse": {
            "mesh_term": "Methotrexate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "refractory", 
            "intolerant", 
            "non-hematologic", 
            "solid tumors"
        ], 
        "lastchanged_date": "January 22, 2014", 
        "location": {
            "contact": {
                "email": "nkv@uic.edu", 
                "last_name": "Neeta Venepalli, MD", 
                "phone": "312-413-2746"
            }, 
            "contact_backup": {
                "email": "alishaw@uic.edu", 
                "last_name": "Alisha Williams, RN", 
                "phone": "(312) 413-2746"
            }, 
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60612"
                }, 
                "name": "University of Illinois at Chicago"
            }, 
            "investigator": {
                "last_name": "Neeta Venepalli, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "STM-02: Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R", 
        "overall_contact": {
            "email": "nkv@uic.edu", 
            "last_name": "Neeta Venepalli, MD", 
            "phone": "(312) 413-2746"
        }, 
        "overall_contact_backup": {
            "email": "alishaw@uic.edu", 
            "last_name": "Alisha Williams, RN", 
            "phone": "(312) 413-2746"
        }, 
        "overall_official": {
            "affiliation": "University of Illinois at Chicago", 
            "last_name": "Neeta Venepalli, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: UIC Cancer Center Data and Safety Monitoring Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective is to determine the maximum tolerated dose (MTD) of 765IGF-MTX by evaluation of toxicity for the treatment of advanced, previously treated malignancies that express IGF-1R.", 
            "measure": "Maximum Tolerated Dose (MTD)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 30 days after final dose."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02045368"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Illinois at Chicago", 
            "investigator_full_name": "Neeta Venepalli", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Characterize adverse effects (AE) of 765IGF-MTX in patients with advanced, previously treated malignancies.", 
                "measure": "Adverse Effects", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after last dose study drug."
            }, 
            {
                "description": "Evaluate clinical response of 765IGF-MTX in patients with advanced, previously treated malignancies.  Disease response will be assessed every 8 weeks while on study treatment using the Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1).", 
                "measure": "Disease Response based on RECIST Criteria", 
                "safety_issue": "No", 
                "time_frame": "Up to 8 weeks after last dose study drug."
            }
        ], 
        "source": "University of Illinois at Chicago", 
        "sponsors": {
            "collaborator": {
                "agency": "IGF Oncology, LLC", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Illinois at Chicago", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}